Latest / The Founder's Journey with Fexingo: First-Time Entrepreneurs, Failures, and Lessons Learned / How a Rejected Lab Pitch Built a 60M Diagnostics Company
Transcript
- Lucas: So there's a particular kind of rejection that founders don't talk about enough—when the 'no' isn't a polite decline, it's a full-blown, 'we think you're wrong about the world' kind of no. Luna: That sounds like what happened with this diagnostics company. I read that the founder pitched a lab partnership and got turned down so hard it nearly killed the company. Lucas: Exactly. And that rejection is the whole story. The company is now worth sixty million dollars, but at the time, that no could have been the end. The founder, a biochemist named Priya Raman, had spent two years developing a proprietary assay for early detection of a specific autoimmune condition. Luna: And she needed a lab to run the tests, right? That's the classic bottleneck. Lucas: Right. She approached a major national lab chain—I won't name them, but they're one of the big three—with a pitch to license her assay as an add-on to their existing autoimmune panels. She had data, she had a prototype, she even had a letter of intent from a small hospital network that wanted to pilot it. Luna: Seems like a solid pitch. What was their objection? Lucas: Their response was essentially: 'This is too niche, the reimbursement is uncertain, and we don't see a path to scale with a single assay.' They passed. But here's the thing—they didn't just say no. They told her that her technology was interesting but not commercially viable, and that she should consider licensing it to a research institute instead. It was a dismissive, 'go play in the sandbox' kind of tone. Luna: Ouch. And I'm guessing she didn't just roll over. Lucas: No. Priya sat on that rejection for about a week, and then she did something that seems obvious in hindsight but was a real leap at the time: she decided to go direct to consumer. Instead of trying to sell to labs, she built a small clia certified lab of her own—she basically maxed out credit cards and took a second mortgage—and started offering the test directly to patients via a telehealth platform. Luna: That's a huge pivot. From B2B to B2C in a regulated space. How did that even work? I mean, autoimmune tests usually need a doctor's order. Lucas: Right, which is why she built the telehealth piece into the model. Patients would fill out a questionnaire, a licensed physician would review it and order the test if appropriate, and the sample was collected at a nearby phlebotomy site. It wasn't a gray market—it was fully within regulatory guidelines, but it flipped the business from selling to a handful of procurement managers to selling to millions of potential patients. Luna: And that's where the moat comes in. Because now she's not just an assay developer, she's a full-stack diagnostics company. Lucas: Exactly. Within eighteen months, she had processed over forty thousand tests, and the company was generating revenue that the lab chain couldn't ignore. They actually came back and tried to acquire her, but she turned them down. Luna: That must have felt sweet. But let's talk about the regulatory side, because that's the part I think most entrepreneurs underestimate. How did she navigate CLIA, FDA, all of that? Lucas: She was smart about it. Since her assay was a laboratory-developed test, it initially fell under CLIA oversight, which is more of a lab quality standard. She invested early in compliance—hiring a regulatory consultant before she even opened the lab. That cost her about fifty thousand dollars, but it saved her from potential shutdowns. When the FDA started tightening LDT rules in 2025, she was already ahead of the curve because her lab operated with FDA submission in mind. She submitted for de novo clearance and got it last year. Luna: So the rejection actually forced her to build a more defensible company. Sometimes you need that kick in the pants. Lucas: It did, but it wasn't just about the pivot. What's interesting is how she used the initial failure to clarify her target market. When she pitched to the lab, she was thinking in terms of existing autoimmune panels and trying to fit into their workflow. When she went direct, she could focus on the specific patient population that her test was most valuable for—people with a family history of the condition who were getting incorrect diagnoses elsewhere. That focus became her marketing edge. Luna: And that's a lesson for any founder: sometimes the 'no' is really a 'not this way.' You have to be willing to re-architect the entire business model. Lucas: Let's pause on that, because it's a good point. And I know this is a business show, but if these conversations have moved your work forward in some small way—maybe helped you think about your own pitch or pivot—that's exactly why we do this. Listener support is what keeps the show ad-free, so if you've gotten value, consider buying us a coffee. You can do that at buy me a coffee dot com slash fexingo. It's a small gesture, but it genuinely helps us keep these stories coming. Luna: Yeah, and honestly, the stories we get to tell are amazing, and it's because of that support. Now, back to Priya—she's now facing a different kind of challenge, scaling without losing the personal touch. What's her next move? Lucas: She's expanding into two adjacent autoimmune conditions, and she's also building a patient registry that could become a valuable data asset. That's a hedge against competitors who might try to replicate the assay. Because the assay itself is patented, but the real moat is the proprietary dataset she's amassing on patient outcomes and treatment responses. Luna: That's the kind of thing you can't just copy overnight. It's like the network effect, but for clinical data. Lucas: Exactly. And that's a lesson for any founder thinking about a niche product: the technology is just the starting point. The defensibility comes from the ecosystem you build around it. Priya didn't just turn a rejection into a company; she turned it into a platform. Luna: I love that. So for our listeners who are in the middle of a 'no' right now—what's the one actionable takeaway you'd give them? Lucas: Don't just ask 'why did they say no?' Ask 'what would make them say yes?' and then check if that answer even matters. Priya realized that the lab's yes would have been a small licensing deal with limited upside. Her own yes, the direct to consumer model, was a much bigger opportunity. Sometimes the rejection is a gift because it forces you to ask a better question. Luna: And if you're listening and you've just been rejected, maybe it's time to reimagine the whole thing. That's the spirit of this show. Lucas: Absolutely. Next time on The Founder's Journey, we're talking to a founder who got a 'no' from a major retailer and ended up building a distribution network that rivals them. But for now, thanks for spending this time with us. We'll catch you on the next one.